Healthcare / Medical DevicesShenzhen
$46.08
-0.93 (-1.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $517.6M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.9B
P/E
24.5x
↑EV/EBITDA
14.2x
↑ROE
7.6%
↑Gross Margin
53.2%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
15.3%
FCF / Net income
1.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.39B · net income $371.6M · FCF $517.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.39B | $3.39B | $2.98B | $2.85B | $2.98B |
| Net Income | $371.6M | $371.6M | $311.8M | $254.3M | $301.7M |
| EBITDA | $625.9M | $625.9M | $551.7M | $435.4M | $444.9M |
| EPS | 1.81 | 1.81 | 1.51 | 1.24 | 1.45 |
| Gross Margin | 53.2% | 53.2% | 51.9% | 43.3% | 39.5% |
| Operating Margin | 11.7% | 11.7% | 12.1% | 9.7% | 11.0% |
| Net Margin | 11.0% | 11.0% | 10.5% | 8.9% | 10.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.19 | 0.13 | 0.09 |
| Current Ratio | 2.41 | 2.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $517.6M | $517.6M | $542.9M | $20.6M | $-540.9M |
| Returns | |||||
| ROE | 7.6% | 7.6% | 6.5% | 5.2% | 6.0% |
| Valuation | |||||
| P/E | 24.51 | 24.51 | 22.22 | 29.01 | 25.41 |
| EV/EBITDA | 14.16 | 14.16 | 11.88 | 14.81 | 15.02 |
| P/B | 1.94 | 1.94 | 1.44 | 1.51 | 1.53 |
| Growth & Yield | |||||
| Revenue Growth | 13.6% | 13.6% | 4.5% | -4.1% | — |
| EPS Growth | 19.9% | 19.9% | 21.8% | -14.5% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.2%
EPS terminal req.
$4.09
Spread vs growth
-11.3%
5Y implied EPS CAGR
22.3%
EPS terminal req.
$4.95
Spread vs growth
-2.4%
10Y implied EPS CAGR
16.0%
EPS terminal req.
$7.97
Spread vs growth
3.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.9%
Start / end P/E
22.0x → 25.5x
EPS bridge
1.51 → 1.81
Residual
+3.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.